Manuscripts and Publications
Filters: Keyword is Female [Clear All Filters]
Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions.. AIDS Patient Care STDS. 23(3):185-94.
.
2009. Patterns of disclosure among youth who are HIV-positive: a multisite study.. J Adolesc Health. 50(3):315-7.
.
2012. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.. J Int AIDS Soc. 22(2):e25252.
.
2019. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
.
2008. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.. Antimicrob Agents Chemother. 55(11):5294-9.
.
2011. Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018. Ann Epidemiol. 45:24-31.e3.
.
2020. Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.. AIDS Patient Care STDS. 30(7):324-38.
.
2016. Predictors of condom use in a multisite study of high-risk youth living with HIV.. AIDS Educ Prev. 22(1):1-14.
.
2010. Predictors of medication adherence in high risk youth of color living with HIV.. J Pediatr Psychol. 35(6):593-601.
.
2010. Predictors of Self-Reported Adherence to Antiretroviral Medication in a Multisite Study of Ethnic and Racial Minority HIV-Positive Youth.. J Pediatr Psychol. 41(4):419-28.
.
2016. Predictors of unprotected sex among young sexually active African American, Hispanic, and White MSM: the importance of ethnicity and culture.. AIDS Behav. 12(3):459-68.
.
2008. Prevalence and correlates of substance use among youth living with HIV in clinical settings.. Drug Alcohol Depend. 169:11-18.
.
2016. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States.. AIDS Patient Care STDS. 24(2):97-104.
.
2010. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
.
2012. Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth.. J Med Virol. 88(11):1944-52.
.
2016. Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.. AIDS. 30(6):889-98.
.
2016. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.
.
2006. Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.. J Acquir Immune Defic Syndr. 61(4):499-506.
.
2012. Preventive misconception and adolescents' knowledge about HIV vaccine trials.. J Med Ethics. 39(12):765-71.
.
2013. Profiles of Risk Among HIV-Infected Youth in Clinic Settings.. AIDS Behav. 19(5):918-30.
.
2015. Programmatic capacity and HIV structural change interventions: influences on coalitions' success and efficiency in accomplishing intermediate outcomes.. J Prev Interv Community. 40(2):118-30.
.
2012. Project ACCEPT: Evaluation of a Group-Based Intervention to Improve Engagement in Care for Youth Newly Diagnosed with HIV.. AIDS Behav. 22(8):2650-2661.
.
2018. Project ORE: A friendship-based intervention to prevent HIV/STI in urban African American adolescent females.. Health Educ Behav. 37(1):115-32.
.
2010. Psychological symptoms among 2032 youth living with HIV: a multisite study.. AIDS Patient Care STDS. 29(4):212-9.
.
2015. Psychosocial factors and substance use in high-risk youth living with HIV: a multi-site study.. AIDS Care. 22(4):475-82.
.
2010. Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States.. Pediatr Infect Dis J. 29(6):530-4.
.
2010. Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.. J Acquir Immune Defic Syndr. 68(2):169-77.
.
2015. Risk perceptions after human papillomavirus vaccination are not subsequently associated with riskier behaviors or sexually transmitted infections in HIV-infected young women.. Hum Vaccin Immunother. 15(7-8):1732-1736.
.
2019. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women.. J Adolesc Health. 50(5):464-70.
.
2012. The role of community resource assessments in the development of 15 adolescent health community-researcher partnerships.. Prog Community Health Partnersh. 2(1):31-9.
.
2008. Safety and Effectiveness of Same-Day Chlamydia trachomatis and Neisseria gonorrhoeae Screening and Treatment Among Gay, Bisexual, Transgender, and Homeless Youth in Los Angeles, California, and New Orleans, Louisiana.. Sex Transm Dis. 47(1):19-23.
.
2020. Self-Efficacy for Sexual Risk Reduction and Partner HIV Status as Correlates of Sexual Risk Behavior Among HIV-Positive Adolescent Girls and Women.. AIDS Patient Care STDS. 29(6):346-53.
.
2015. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
.
2012. Sexual risk taking among transgender male-to-female youths with different partner types.. Am J Public Health. 100(8):1500-5.
.
2010. Sexually Transmitted Infection Positivity Among Adolescents With or at High-Risk for Human Immunodeficiency Virus Infection in Los Angeles and New Orleans.. Sex Transm Dis. 46(11):737-742.
.
2019. Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy.. J Clin Virol. 102:7-11.
.
2018. Situated Vulnerabilities, Sexual Risk, and Sexually Transmitted Infections' Diagnoses in a Sample of Transgender Youth in the United States.. AIDS Patient Care STDS. 33(3):120-130.
.
2019. Social Support and Human Immunodeficiency Virus-Status Disclosure to Friends and Family: Implications for Human Immunodeficiency Virus-Positive Youth.. J Adolesc Health. 57(1):73-80.
.
2015. Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.. J Leukoc Biol. 103(4):671-680.
.
2018. Spilling the T on Trans-Misogyny and Microaggressions: An Intersectional Oppression and Social Process Among Trans Women.. J Homosex. 66(10):1415-1438.
.
2019. Stigma reduction in adolescents and young adults newly diagnosed with HIV: findings from the Project ACCEPT intervention.. AIDS Patient Care STDS. 28(10):543-54.
.
2014. Strategies and outcomes of HIV status disclosure in HIV-positive young women with abuse histories.. AIDS Patient Care STDS. 27(3):191-200.
.
2013. Stressors and sources of support: the perceptions and experiences of newly diagnosed Latino youth living with HIV.. AIDS Patient Care STDS. 26(5):281-90.
.
2012. Structural and Community Change Outcomes of the Connect-to-Protect Coalitions: Trials and Triumphs Securing Adolescent Access to HIV Prevention, Testing, and Medical Care.. Am J Community Psychol. 60(1-2):199-214.
.
2017. Structural Determinants of Antiretroviral Therapy Use, HIV Care Attendance, and Viral Suppression among Adolescents and Young Adults Living with HIV.. PLoS One. 11(4):e0151106.
.
2016. Structural Effects on HIV Risk Among Youth: A Multi-level Analysis.. AIDS Behav. 22(11):3451-3467.
.
2018. Substance abuse treatment for HIV infected young people: an open pilot trial.. J Subst Abuse Treat. 46(2):244-50.
.
2014. Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.. AIDS Patient Care STDS. 26(4):193-6.
.
2012. .
2012. Targeting Structural Change for HIV Prevention: A Process and Tool for Community Application.. Health Promot Pract. 16(6):837-48.
.
2015. "Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.. AIDS Behav. 16(7):1761-74.
.
2012. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
.
2018. Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.. AIDS Res Hum Retroviruses. 35(8):746-754.
.
2019. Tobacco Use and Sustained Viral Suppression in Youth Living with HIV.. AIDS Behav. 22(6):2018-2025.
.
2018. Transgender and Other Gender-Diverse Youth's Progression Through the HIV Continuum of Care: Socioecological System Barriers.. AIDS Patient Care STDS. 33(1):32-43.
.
2019. Transitioning HIV-Positive Adolescents to Adult Care: Lessons Learned From Twelve Adolescent Medicine Clinics.. J Pediatr Nurs. 31(5):537-43.
.
2016. Understanding Care Linkage and Engagement Across 15 Adolescent Clinics: Provider Perspectives and Implications for Newly HIV-Infected Youth.. AIDS Educ Prev. 29(2):93-104.
.
2017. The use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial.. AIDS Behav. 18(4):686-96.
.
2014. Use of geographic information systems for planning HIV prevention interventions for high-risk youths.. Am J Public Health. 97(11):1974-81.
.
2007. The Usefulness of the CRAFFT in Screening for Problematic Drug and Alcohol Use Among Youth Living with HIV.. AIDS Behav. 21(7):1868-1877.
.
2017. Using Syndemics Theory to Investigate Risk and Protective Factors Associated with Condomless Sex Among Youth Living with HIV in 17 U.S. Cities.. AIDS Behav. 21(3):833-844.
.
2017. Using technology to assess and intervene with illicit drug-using persons at risk for HIV.. Curr Opin HIV AIDS. 12(5):458-466.
.
2017. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.. Cult Health Sex. 14(2):151-66.
.
2012. Victimization and sexual risk behavior in young, HIV positive women: exploration of mediators.. AIDS Behav. 16(4):999-1010.
.
2012. Vitamin D status in adolescents and young adults with HIV infection.. Am J Clin Nutr. 83(5):1135-41.
.
2006. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
.
2012. .
2014. .
2018. What HIV-positive young women want from behavioral interventions: a qualitative approach.. AIDS Patient Care STDS. 26(5):291-7.
.
2012. Young Women Living with HIV: Outcomes from a Targeted Secondary Prevention Empowerment Pilot Trial.. AIDS Patient Care STDS. 30(5):229-35.
.
2016. Young women's experience with using videoconferencing for the assessment of sexual behavior and microbicide use.. Telemed J E Health. 19(11):866-71.
.
2013. "Youth friendly" clinics: considerations for linking and engaging HIV-infected adolescents into care.. AIDS Care. 26(2):199-205.
.
2014. Youth living with HIV and partner-specific risk for the secondary transmission of HIV.. Sex Transm Dis. 36(7):439-44.
.
2009. Youth living with HIV and problem substance use: elevated distress is associated with nonadherence and sexual risk.. J Int Assoc Physicians AIDS Care (Chic). 9(2):113-5.
.
2010.